The presented subanalysis of Teri-PRO assessed changes in treatment satisfaction over 48 weeks in relapsing MS patients, stratified by age, who switched to teriflunomide 14 mg from prior DMTs. Four groups were identified:
- ≤35 years (n=85);
- >35 to ≤45 years (n=167);
- >45 to ≤55 years (n=175); and
- >55 years (n=129).
Patients rated their satisfaction using the highly-validated Treatment Satisfaction Questionnaire for Medication (TSQM), version 1.4. Its 4 domains are: global satisfaction, effectiveness, side effects, and convenience. Scores are between 0 and 100, from lower to higher satisfaction. Assessment was done at baseline, when actually the prior DMT was evaluated, and again at week 48, when patients rated satisfaction over the past 2-3 weeks or since last use of medication.
Least-squares mean change (LS) in each TSQM domain was significantly improved at week 48 compared with baseline in all patients aged >35 years:
- >35 to ≤45 years: global satisfaction, 15.0 (P<0.0001); effectiveness, 6.3 (P=0.0157); side effects, 20.6 (P<0.0001); convenience, 31.6 (P<0.0001).
- >45 to ≤55 years: global satisfaction, 15.4 (P<0.0001); effectiveness, 8.3 (P<0.0001); side effects, 20.4 (P<0.0001; convenience, 31.0 (P<0.0001).
- >55 years: global satisfaction, 11.3 (P=0.0001); effectiveness, 9.3 (P=0.0001); side effects, 11.7 (P<0.0001); convenience, 29.8 (P<0.0001).
In the group of patients aged ≤35 years, improvements in 2 domains reached significance: side effects (26.2, P<0.0001) and convenience (28.7, P<0.0001); the other 2 domains showed a numerical positive trend.
- Coyle P, et al. Treatment Satisfaction Across Age Groups in Patients Who Switched to Teriflunomide: Analysis of the Real-world Teri-PRO Study. MSVirtual 2020, Abstract P1065.
Posted on
Previous Article
« Safety and efficacy of cladribine, glatiramer acetate, and more Next Article
TERIKIDS trial extension of teriflunomide in paediatric MS »
« Safety and efficacy of cladribine, glatiramer acetate, and more Next Article
TERIKIDS trial extension of teriflunomide in paediatric MS »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
November 25, 2020
Low-dose rituximab as effective as high-dose, but safer
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/06/Figure-Brain-ATP-is-reduced-in-VDRF-positive-MS-patients.png)
June 16, 2021
Dysmetabolism may drive MS progression
![](https://conferences.medicom-publishers.com/wp-content/uploads/2023/12/Figure-Primary-outcome-time-to-first-relapse-1024x609.png)
December 4, 2023
Prioritising high efficacy therapies in children with MS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com